RxDoctor Payments Data

David van Duin, MD

Infectious Disease · Chapel Hill, NCNPI 1225124621

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $64,335 of the $67,390 with a category attached, or 95.5%. 8 manufacturers reported payments, led by F. Hoffmann-la Roche AG at 44.5% of the total. Reporting peaked in 2021 at $21,475 and has fallen 90.8% since, to $1,968 in 2025. Among infectious disease clinicians in NC with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$67,390in general payments, 2019–2025

Across 43 payments — averaging $1567.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • F. Hoffmann-la Roche AG$30K
  • Merck$11K
  • Genentech, Inc.$11K
  • AbbVie$8K
  • Shionogi Inc$5K
  • Melinta Therapeutics, LLC$2K
  • plus $768 from 2 others
$369,816in research payments, 2019–2025

Across 4 payments — averaging $92,454 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Merck$370K

What the payments were for

  • Consulting fees$64,33595%
  • Travel & lodging$2,2313%
  • Food & beverage$8241%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$67,390 in reported general payments places this provider in the 95th percentile of 250 infectious disease providers in North Carolina.

See all infectious disease providers in North Carolina

Medicare billing

Part B allowed, 2024
$17,803
Medicare patients
67
Services billed
164

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other infectious disease in Chapel Hill

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →